Successful immune tolerance in two children with severe haemophilia A

1. Darby SC, Keeling DM, Spooner RJ, et al. The incidence of factor VIII and factor IX inhibitors in the haemophilia population of the UK and their effect on subsequent mortality, 1977B99. J Thromb Haemost 2004; 2:1047B1054.10.1046/j.1538-7836.2004.00710.xSearch in Google Scholar

2. Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594B598.10.1016/0140-6736(92)90874-3Search in Google Scholar

3. Roberts HR, Monroe DM, White GC. The use of recombinate factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858B3864.10.1182/blood-2004-06-222315328151Open DOISearch in Google Scholar

4. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1997; 55: 638B648.10.1038/clpt.1994.808004880Search in Google Scholar

5. Yatuv R, Dayan I, CarmelBGoren L, et al. Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes. Haemophilia 2008; 14: 476B48310.1111/j.1365-2516.2008.01741.x18393980Open DOISearch in Google Scholar

6. Weimer T, Wormsbächer W, Kronthaler U, et al. Prolonged inBvivo half life of factor VIIa by fusion to albumin. Thromb Haemost 2008; 99: 659B66710.1160/TH07-08-052518392323Search in Google Scholar

7. Leissinger C, Gringeri A, Antmen B, et al. AntiBinhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684B92.10.1056/NEJMoa110443522047559Search in Google Scholar

8. MancoBJohnson MJ, Abshire TC, Schapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe haemophilia. N Engl J Med 2007; 357: 535B544.10.1056/NEJMc07262318003967Search in Google Scholar

9. Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in haemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904B1913.10.1111/j.1538-7836.2007.02663.x17723130Open DOISearch in Google Scholar

10. Hay CR, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335B134410.1182/blood-2011-08-36913222101900Search in Google Scholar

11. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52B57.10.1055/s-0037-1612943Search in Google Scholar

12. Mariani G, Kroner B. Immune Tolerance in haemophilia with factor VIII inhibitors: predictors of success. Haematologica 2001; 86: 1186B1193.Search in Google Scholar

13. Kruez W, Ettingshausen CE, Zyschka A, et al. Inhibitor development in previously untreated patients with haemophilia A: a prospective longBterm followBup comparing plasmaBderived and recombinant products. Semin Thromb Hemost 2002; 28: 285B 290.10.1055/s-2002-3266412098090Open DOISearch in Google Scholar

13. Kruez W. Immune tolerance and choice of concentrates. In: Lee C, ed. Inhibitors in patients with haemophilia. Oxford: Blackwell Science Ltd. 2002; 55B56.10.1002/9780470757260.ch9Search in Google Scholar

14. Berntorp E. Importance of rapid bleeding control in haemophilia complicated by inhibitors. Haemophilia 2001; 17: 11B16.10.1111/j.1365-2516.2010.02337.x20565546Search in Google Scholar